-
Posted by
Two Blokes Jun 26 -
Filed in
Stock
-
3 views
Pfizer's post-pandemic revenue decline is temporary; new launches like Abrysvo and Adcetris, plus Seagen integration, position it for a 2025 turnaround. Valuation is compelling: Pfizer trades at deep discounts on P/E, EV/EBITDA, and P/B, with a strong 8.2% FCF yield and sector-leading 7% dividend. Risks include patent cliffs, U.S. drug price regulation, and R&D setbacks, but robust margins and pipeline support long-term growth.
